Garyphallia Poulakou

Thromboembolic risk and anticoagulant therapy in COVID‐19 patients: emerging evidence and call for action

Konstantinos G. Kyriakoulis, Evangelos Dimakakos, Garyphallia Poulakou et al. · British Journal of Haematology · 2020 · 521 citations · Full text

Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study

Belén Gutiérrez‐Gutiérrez, Elena Salamanca, Marina de Cueto et al. · The Lancet Infectious Diseases · 2017 · 511 citations · Full text

Appropriate Combination Therapy, Retrospective Cohort Study, Antimicrobial Stewardship +10

An Outbreak of Infection due to β‐Lactamase<i>Klebsiella pneumoniae</i>Carbapenemase 2–Producing<i>K. pneumoniae</i>in a Greek University Hospital: Molecular Characterization, Epidemiology, and Outcomes

Maria Souli, Irene Galani, Anastasia Antoniadou et al. · Clinical Infectious Diseases · 2009 · 272 citations · Full text

Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria

Konstantinos Pontikis, Ilias Karaiskos, Styliani Bastani et al. · International Journal of Antimicrobial Agents · 2013 · 220 citations

Antimicrobial Susceptibility, Health Sciences, Antibiotics +8

An open label trial of anakinra to prevent respiratory failure in COVID-19

Evdoxia Kyriazopoulou, Periklis Panagopoulos, Symeon Metallidis et al. · eLife · 2021 · 180 citations · Full text